Folate deficiency and folic acid supplementation: The prevention of neural-tube defects and congenital heart defects

Nutrients

Volumn 5, Issue 11, 2013, Pages 4760-4775

  Czeizel, Andrew E ^a   Dudás, Istvan ^a   Vereczkey, Attila ^b   Bánhidy, Ferenc ^c  

^a FOUNDATION FOR THE COMMUNITY CONTROL OF HEREDITARY DISEASES   (Hungary)

^b Versys Clinics   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Congenital heart defects; Folic acid; Multivitamins; Neural tube defects; Primary prevention

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); AMINOPTERIN; CYANOCOBALAMIN; CYSTATHIONINE BETA SYNTHASE; FOLIC ACID; GAMMA GLUTAMYL HYDROLASE; GLYCINE HYDROXYMETHYLTRANSFERASE; HOMOCYSTEINE; METHIONINE; PLACEBO; PTEROPTIN; PYRIDOXAL 5 PHOSPHATE; PYRIDOXINE; RETINOL; RIBOFLAVIN; TETRAHYDROFOLIC ACID; TRIMETHOPRIM;

ANENCEPHALUS; CONGENITAL HEART MALFORMATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIET SUPPLEMENTATION; DIETARY INTAKE; FIRST TRIMESTER PREGNANCY; FOLIC ACID DEFICIENCY; HUMAN; HYPERHOMOCYSTEINEMIA; NEURAL TUBE DEFECT; NONHUMAN; PERICONCEPTIONAL SUPPLEMENTATION; PREVALENCE; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RISK REDUCTION; VITAMIN SUPPLEMENTATION;

DIET; DIETARY SUPPLEMENTS; FLOUR; FOLIC ACID; FOLIC ACID DEFICIENCY; FOOD, FORTIFIED; HEART DEFECTS, CONGENITAL; HUMANS; NEURAL TUBE DEFECTS;

EID: 84888166691     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu5114760     Document Type: Review

References (80)

1. Hale, F. Pigs born without eyeballs. J. Hered. 1932, 24, 105-109.
2. Warkany, J. Congenital malformations induced by maternal dietary deficiency: Experiments and their interpretation. Harvey Lect. 1952-1953, 48, 89-102.
3. Nelson, M.M. Mammalian Fetal Development and Antimetabolities. In Antimetabolites and Cancer;Rhoads, E.P., Ed.;American Association for the Advancement of Science Monograph: Washington, DC, USA, 1955;pp. 61-79.
4. Thiersch, J.B. Therapeutic abortions with a folic acid antagonist, 4-aminopteroylglutamic acid (4-amino PGA) administered by the oral route. Am. J. Obstet. Gynecol. 1952, 3, 1298-1304.
5. Meltzer, H.J. Congenital anomalies due to attempted abortion with 4-aminopteroylglutamic acid. J. Am. Med. Assoc. 1956, 161, 1253-1254.
6. Warkany, J.;Beaudry, P.H.;Hornstein, S. Attempted abortion with 4-aminopteroylglutamic acid (aminopterin): Malformations of the child. Am. J. Dis. Child. 1959, 97, 274-281.
7. Hernandez-Diaz, S.;Werler, M.M.;Walker, A.M.;Mitchell, A.A. Folic acid antagonists during pregnancy and risk of birth defects. N. Engl. J. Med. 2000, 343, 1608-1614.
8. Czeizel, A.E.;Rockenbauer, M.;Sørensen, H.A.T.;Olsen, J. The teratogenic risk of trimethoprim-sulfonamides: A population-based case-control study. Reprod. Toxicol. 2001, 15, 637-646.
9. Hibbard, B.M. The role of folic acid in pregnancy with particular reference to anaemia, abruption and abortion. J. Obstet. Gynecol. Br. Commonw. 1964, 71, 529-542.
10. Hibbard, E.D.;Smithells, R.W. Folic acid metabolism and human embryopathy. Lancet 1965, 285, 1254.
11. Smithells, R.W.;Sheppard, S.;Schorah, C.J. Vitamin deficiencies and neural tube defects. Arch. Dis. Child. 1976, 51, 944-950.
12. Czeizel, A.E. Specified critical period of different congenital abnormalities: A new approach for human teratology. Congenit. Anom. 2008, 48, 103-109.
13. Czeizel, A.E. Definition, classification, prevalence and economic burden of neural tube defects. Gynaecol. Forum 2010, 15, 9-12.
14. Smithells, R.W.;Sheppard, S.;Schorah, C.J.;Seller, M.J.;Nevin, N.C.;Harris, R.;Read, A.P.;Fielding, D.W. Possible prevention of neural tube defects by periconceptional vitamin supplementation. Lancet 1980, 1, 339-340.
15. Smithells, R.W.;Sheppard, S.;Wild, J.;Schorah, C.J. Prevention of neural tube defect recurrences in Yorkshire: Final report. Lancet 1989, 2, 498-499.
16. Nevin, N.C.;Seller, M.J. Prevention of neural tube defect recurrences. Lancet 1990, 335, 178-179.
17. MRC Vitamin Study Research Group. Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study. Lancet 1991, 338, 131-137.
18. Czeizel, A.E. Ten years of experience in the periconceptional care. Eur. J. Obstet. Gynecol. Reprod. Biol. 1999, 84, 43-49.
19. Czeizel, A.E.;Dudás, I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N. Engl. J. Med. 1992, 327, 1832-1835.
20. Czeizel, A.E.;Dobó, M.;Vargha, P. Hungarian two-cohort controlled study of periconceptional multivitamin supplementation shows reduction in certain congenital abnormalities. Birth Defects Res. 2004, 70, 853-861.
21. Czeizel, A.E.;Medveczki, E. Periconceptional multivitamin supplementation and multimalformed offspring. Obstet. Gynecol. 2003, 102, 1255-1261.
22. Berry, R.J.;Li, Z.;Erickson, J.D.;Li, S.;Moore, C.A.;Wang, H.;Mulinare, J.;Zhao, P.;Wong, L.Y.;Gindler, J.;et al. Prevention of neural-tube defects with folic acid in China. China-US Collaborative Project for Neural Tube Defect Prevention. N. Engl. J. Med. 1999, 341, 1485-1490.
23. Wills, L. Treatment of "pernicious anaemia" of pregnancy and "tropical anaemia" with special reference to yeast extract as a curative agent. Br. Med. J. 1931, 1, 1059-1064.
24. Hoffbrand, A.V. The history of folic acid. Br. J. Haematol. 2001, 113, 579-589.
25. McPartlin, J.;Halligan, A.;Scott, J.M.;Darling, M.;Weir, D.G. Accelerated folate breakdown in pregnancy. Lancet 1993, 341, 148-149.
26. Daly, L.E.;Kirke, P.N.;Molloy, A.;Weir, D.G.;Scott, J.M. Folate levels and neural tube defects. Implications for prevention. J. Am. Med. Assoc. 1995, 274, 1698-1702.
27. Brämswig, S.;Prinz-Langenohl, R.;Lamers, Y.;Tobolski, O.;Wintergerst, E.;Berthold, H.K.;Pietrzik, K. Supplementation with a multivitamin containing 800 microgram of folic acid shortens the time to reach the preventive red blood cell folate concentration in healthy women. Int. J. Vitam. Nutr. Res. 2009, 79, 61-70.
28. Food Safety Authority of Ireland. National Committee on Folic Acid Food Fortification;Food Safety Authority of Ireland: Dublin, UK, 2006.
29. Czeizel, A.E.;Dudás, I.;Paput, L.;Bánhidy, F. Prevention of neural-tube defects with periconceptional folic acid, methylfolate, or multivitamins? Ann. Nutr. Metab. 2011, 58, 263-271.
30. Goyette, D.;Summer, J.S.;Milos, R. Human methylenetetrahydrofolate reductase: Isolation of cDNA, mapping and mutation identification. Nat. Genet. 1994, 7, 195-200.
31. Frosst, P.;Blom, H.J.;Milos, R. A candidate genetic risk-factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 1995, 10, 111-113.
32. Wilcken, B.;Bamforth, F.;Li, Z.;Ritvanen, A.;Redlung, M.;Stoll, C.;Alembik, Y.;Dott, B.;Czeizel, A.E.;Gelman-Kohan, Z.;et al. Geographical and ethnic variation of the 677C/T allele of 5,10-methylenetetrahydrofolate reductase (MTHFR): Findings from over 7000 newborns from 16 areas worldwide. J. Med. Genet. 2003, 40, 619-625.
33. Wright, A.J.A.;King, M.J.;Finglas, P.M. Folate-supplemented oral contraceptives: Does 6S-5-methytetrahydrofolic acid (Metafolin®) offer advantages over folic acid? Gynaecol. Forum 2010, 15, 29-32.
34. Coop, A.J.;Greene, N.D.E. Genetics and development of neural tube defects. J. Pathol. 2010, 220, 217-230.
35. Greene, N.D.;Stanier, P.;Moore, G.E. The emerging role of epigenetic mechanism in the aetiology of neural tube defects. Epigenetics 2011, 6, 875-883.
36. Suzuki, M.;Morita, H.;Ueno, N. Molecular mechanism of cell shape changes that contribute to vertebrate neural tube closure. Dev. Growth Differ. 2012, 54, 266-276.
37. Massarwa, R.;Niswander, L. In toto live imaging of mouse morphogenesis and new insights into neural tube closure. Development 2013, 140, 223-236.
38. Czeizel, A.E. Reduction of urinary tract and cardiovascular defects by periconceptional multivitamin supplementation. Am. J. Med. Genet. 1996, 62, 179-183.
39. Botto, L.D.;Khoury, M.J.;Mulinare, J.;Erickson, J.D. Periconceptional multivitamin use and the occurrence of conotruncal heart defects. Results from a population based case-control study. Pediatrics 1996, 98, 911-917.
40. Botto, L.D.;Mulinare, J.;Erickson, J.D. Occurrence of congenital heart defects in relation to maternal multivitamin use. Am. J. Epidemiol. 2000, 151, 878-884.
41. Botto, L.D.;Mulinare, J.;Erickson, J.D. Do multivitamin or folic acid supplementation reduce the risk for congenital heart defects? Evidence and gaps. Am. J. Med. Genet. 2003, 121A, 95-101.
42. Czeizel, A.E.;Rockenbauer, M.;Siffel, C.;Varga, E. Description and mission evaluation of the Hungarian case-control surveillance of congenital abnormalities, 1980-1996. Teratology 2001, 63, 176-185.
43. Czeizel, A.E.;Tóth, M.;Rockenbauer, M. Population-based case control study of folic acid supplementation during pregnancy. Teratology 1996, 53, 345-351.
44. Van Beynum, I.M.;Kapusta, L.;Bakker, M.K.;den Heijer, M.;Blom, H.J.;de Walle, H.E. Protective effect of periconceptional folic acid supplements on the risk of congenital heart defects: A registry-based case-control study in the northern Netherlands. Eur. Heart J. 2010, 31, 464-471.
45. Ionescu-Ittu, R.;Marelli, A.J.;Mackie, A.S.;Pilote, L. Prevalence of severe congenital heart disease after folic acid fortification of grain products. Time trend analysis in Quebec, Canada. Br. Med. J. 2009, 338, b1673.
46. Goh, Y.I.;Bollano, E.;Einarson, T.R.;Koren, G. Prenatal multivitamin supplementation and rates of congenital anomalies: A meta-analysis. J. Obstet. Gynaecol. Can. 2006, 28, 680-689.
47. Czeizel, A.E.;Puho, E.;Sorensen, H.T.;Olsen, J. Possible association between congenital abnormalities and use of different sulfonamides during pregnancy. Congenit. Anom. 2004, 44, 79-86.
48. Van Beynum, I.M.;Kapusta, L.;den Heijer, M.;Vermeulen, S.H.;Kouwenberg, M.;Dani, L.S.;Blom, H.J. Maternal MTHFR C>T is a risk factor for congenital heart defects: Effect modification by periconceptional folate supplementation. Eur. Heart J. 2006, 27, 981-987.
49. Wang, W.;Wang, Y.;Gong, F. MTHFR C677T polymorphism and risk of congenital heart defects: Evidence from 129 case-control and TDT studies. PLoS One 2013, 8, e58041.
50. Van Beynum, I.M.;den Heijer, M.;Kapusta, L.;Blom, H.J. The MTHFR 677C-T polymorphism and the risk factor for congenital heart defects: A literature review and meta-analysis. Q. J. Med. 2007, 100, 743-753.
51. Czeizel, A.E.;Susánszky, E. Diet intake and vitamin supplement use of Hungarian women during the preconceptional period. Int. J. Vitam. Nutr. Res. 1994, 64, 300-305.
52. UK Committee on Medical Aspects of Food and Nutrition Policy (COMA). Folic Acid and the Prevention of Disease;TSO: London, UK, 2000.
53. Bower, C.;Wald, N.J. Vitamin B12 deficiency and the fortification of food with folic acid. Eur. J. Clin. Nutr. 1995, 49, 87-93.
54. Cuskelly, G.J.;McNulty, H.;Scott, J.M. Effect of increasing dietary folate on red-cell folate: Implications for prevention of neural tube defects. Lancet 1996, 347, 657-659.
55. Busby, A.;Abramsky, L.;Dolk, H.;Armstrong, B.;Addor, M.C.;Anneren, G.;Armstrong, N.;Baguette, A.;Barisic, J.;Berghold, A.;et al. Preventing neural tube defects in Europe: A missed opportunity. Reprod. Toxicol. 2005, 20, 393-402.
56. Botto, L.D.;Lisi, A.;Robert-Gnansia, E.;Erickson, J.D.;Vollset, S.E.;Mastroiacovo, P. International retrospective cohort study of neural tube defects in relation to folic acid recommendation? Are the recommendation working? Br. Med. J. 2005, 330, 571-582.
57. Neville, A.J.;de Walle, H.E.K. Prevention of neural tube defects by periconceptional folic acid supplementation in Europe. Gynaecol. Forum 2010, 15, 16-20.
58. Bitzer, J.;von Stenglin, A.;Bannemerschultz, R. Women's awareness and periconceptional use of folic acid: Data from a large European survey. Int. J. Women's Health 2013, 5, 201-213.
59. Mason, J.O.;McGinnis, J.M. "Healthy People 2000": An overview of the national health promotion and disease prevention objectives. Public Health Rep. 1990, 105, 441-446.
60. Czeizel, A.E. Experience of the Hungarian Preconception Service between 1984 and 2010. Eur. J. Obstet. Gynecol. Reprod. Biol. 2012, 161, 18-25.
61. Holzgreve, W. Adding folate to the pill to prevent neural tube defects. Gynaecol. Forum 2010, 15, 4-8.
62. CDC. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR 1992, 41, 1233-1238.
63. Daly, S.;Mills, J.L.;Molloy, A.M.;Conley, M.;Lee, Y.J.;Kirke, P.N.;Weir, D.G.;Scott, J.M. Minimum effective dose of folic acid for food fortification to prevent neural-tube defects. Lancet 1997, 350, 1666-1669.
64. U.S. Preventive Service Task Force. Folic acid for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 2009, 150, 626-631.
65. Czeizel, A.E.;Bánhidy, F. Vitamin supply in pregnancy for prevention of congenital abnormalities. Curr. Opin. Clin. Nutr. Metab. Care 2011, 14, 291-296.
66. US Department of Health and Human Services. Food standards: Amendment of standards of identity for enriched grain products to require addition of folic acid. Fed. Regist. 1996, 61, 8781-8787.
67. Honein, M.A.;Paulozzi, L.J.;Mathews, T.J.;Erickson, J.D.;Wong, L.Y. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. J. Am. Med. Assoc. 2001, 285, 2981-2986.
68. Williams, L.J.;Mai, C.;Edmonds, L.D.;Shaw, G.M.;Kirby, R.S.;Hobbs, C.A.;Sever, L.E.;Miller, L.A.;Meaney, F.J.;Lewitt, M. Prevalence of spina bifida and anencephaly during the transition to mandatory folic acid fortification in the United States. Teratology 2002, 66, 33-39.
69. De Wals, P.;Tairou, F.;van Allen, M.;Uh, S.H.;Lowry, R.B.;Sibbald, B.;Evans, J.A.;van den Hof, M.C.;Zimmer, P.;Crowley, M.;et al. Reduction in neural-tube defects after folic acid fortification in Canada. N. Engl. J. Med. 2007, 357, 135-142.
70. Flour Fortification Initiative. Available online: http://www.FFInetwork.org (accessed on 23 April 2013).
71. Wald, N.J.;Law, M.R.;Morris, J.K.;Wald, D.S. Quantifying the effects of folic acid. Lancet 2001, 358, 2069-2073.
72. Koren, G.;Goh, I.Y. Increasing folate supplementation for selected groups of Canadian women. J. Obstet. Gynaecol. Can. 2007, 29, 992-996.
73. Kirke, P.N.;Molloy, A.M.;Daly, L.E.;Burke, H.;Weir, D.G.;Scott, J.M. Maternal plasma folate and vitamin B12 are independent risk factors for neural tube defects. Q. J. Med. 1993, 86, 703-708.
74. Oakley, G.P. Let's increased folic acid fortification and include vitamin B-12. Am. J. Clin. Nutr. 1997, 6, 1989-1990.
75. Mason, J.B.;Dickstein, A.;Jacques, P.G.;Haggarty, P.;Selhub, J.;Dallal, G.;Rosenberg, I.H. A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: A hypothesis. Cancer Epidemiol. Biomark. Prev. 2007, 16, 1325-1329.
76. Fenech, M. The role of folic acid and vitamin B12 in genomic stability of human cells. Mutat. Res. 2001, 475, 57-67.
77. Osterhues, A.;Holzgreve, W.;Michels, K.B. Shall we put the world on folate? Lancet 2009, 374, 959-960.
78. Vollset, S.E.;Clarke, R.;Lewington, S.;Ebbing, M.;Halsey, J.;Lonn, E.;Armitage, J.;Manson, J.E.;Hankey, G.J.;Spence, J.D.;et al. Effect of folic acid supplementation on overall and site-specific cancer incidence during the randomized trials: Meta-analysis of data on 50,000 individuals. Lancet 2013, 381, 1029-1036.
79. Oakley, G.P. Inertia on folic acid fortification: Public health malpractice. Teratology 2002, 66, 44-54.
80. Grosse, S.D.;Waltzman, N.J.;Romano, P.S.;Mulinare, J. Reevaluating the benefits of folic acid fortification in the United States: Economic analysis, regulation, and public health. Am. J. Public Health 2005, 95, 1917-1922.